As ICB monotherapy still does not satisfactorily work in ovarian cancer patients [27], and as the CXCR3 chemokine system has been reported to take part in therapy response to ICB in preclinical cancer models [9, 13], we asked whether CXCL9 overexpression all by itself was sufficient to facilitate a successful anti-PD-L1 therapy. This evidence concerns the gene CXCR3 and ovarian cancer.